Muhammed A. Moukhtar Hammad, MBBCh, discusses Peyronie disease and Dupuytren’s contractures

In this video, Muhammed A. Moukhtar Hammad, MBBCh, discusses the study “Do Peyronie’s Disease Patients With Concomitant Dupuytren’s Contractures Respond Better to Intralesional Injection of Collagenase Clostridium Histolyticum?” which he presented at the 2024 Sexual Medicine Society of North America Fall Scientific Meeting in Scottsdale, Arizona. Hammad is a Masters of Biomedical and Translational Science Candidate at the University of California, Irvine (UCI) School of Medicine and a clinical research fellow at UCI Health – Department of Urology.

Transcription:

Please describe the background for this study.

Dupuytren's contractures are prevalent in men with Peyronie disease, but there are limited data out there on the efficacy of Xiaflex treatment in patients with both Dupuytren's contractures and Peyronie disease. So we wanted to study if Dupuytren's contracture has any effect at all in Xiaflex treatment. To do that, we conducted a retrospective chart review in 573 patients undergoing Peyronie disease treatment via Xiaflex treatment in 1 single academic institution, which is basically University of California, Irvine, where am I a urology research fellow. Basically, we looked at patients' demographics. We compared outcomes in patients with [Peyronie disease] with DC and vs no DC. We wanted to see, are they going to respond better or not? When we looked at the results, it was quite striking.

What were some of the notable findings?

Basically, what we found was regarding demographics, we found that patients with Dupuytren's contractures were generally older and had a shorter onset of Peyronie disease. Basically, it might elucidate to the fact that patients with Dupuytren's contractures are closely monitored, they know a lot of their associated symptoms, they know a lot about their treatment modalities, and therefore opt early enough for Xiaflex treatment and that can attribute to better results. And that's exactly what we saw. Although they had pre treatment composite curvature, which is comparable to the non-DC group, and they had also almost the same number of mean number ofXiaflex treatment injections, we saw that post treatment, the composite curvature degree and percentage of improvement was actually better in the Dupuytren's contracture group than in the non-Dupuytren's contracture group. That was really striking. That was approximately 15% of improvement. That's not to be taken lightly.

There are a lot of theories behind this that we can put on the table. It's beyond the scope of the study, but we can actually look at it more and see, what are the actual reasons behind that? But as far as we know, currently, with this study, is that we're expecting better results in patients with Dupuytren's contractures than those who do not have Dupuytren'scontractures. Some hypotheses that we can happily share, and we're actually looking further into this are, number 1, as I said, a shorter onset. This was an insight that we took from this study. But another one is, Dupuytren's contractures and Peyronie disease, they just go hand in hand. So they might as well be of a certain genetic predisposition, while the non-Dupuytren's contracture group are related more to micro trauma, etc. So if you look at it from this perspective, you can see that genetic predisposition can have something to do with it, but we can't jump to this far stretch conclusion without further exploration, and we hope that we know the reason. But as far as we're concerned, that they're having better results. Thank you.

This transcript was AI generated and edited by human editors for clarit